These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2687716)

  • 21. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.
    Aziz TZ; Peggs D; Sambrook MA; Crossman AR
    Mov Disord; 1991; 6(4):288-92. PubMed ID: 1758446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
    Ghorayeb I; Fernagut PO; Aubert I; Bezard E; Poewe W; Wenning GK; Tison F
    Mov Disord; 2000 May; 15(3):531-6. PubMed ID: 10830420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
    Fredriksson A; Palomo T; Chase T; Archer T
    J Neural Transm (Vienna); 1999; 106(3-4):283-300. PubMed ID: 10392537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
    Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
    Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus.
    Robertson RG; Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1991 Nov; 563(1-2):278-80. PubMed ID: 1786541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rest tremor in rhesus monkeys with MPTP-induced parkinsonism.
    Emborg ME; Tetrud JW; Moirano J; McLaughlin WW; Bankiewicz KS
    Front Biosci; 2003 May; 8():a148-54. PubMed ID: 12700090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
    Fredriksson A; Archer T
    Behav Brain Res; 2003 Feb; 139(1-2):31-46. PubMed ID: 12642174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
    Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
    Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
    Bodis-Wollner I; Chung E; Ghilardi MF; Glover A; Onofrj M; Pasik P; Samson Y
    J Neural Transm Park Dis Dement Sect; 1991; 3(1):63-72. PubMed ID: 2064731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey.
    Boraud T; Bezard E; Guehl D; Bioulac B; Gross C
    Brain Res; 1998 Mar; 787(1):157-60. PubMed ID: 9518590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
    Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
    J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study.
    Vila M; Levy R; Herrero MT; Faucheux B; Obeso JA; Agid Y; Hirsch EC
    Neuroscience; 1996 Apr; 71(4):903-12. PubMed ID: 8684621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.